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TECH N I C A L A DVA N CE S
Despite the advances in cancer immunotherapy, only a fraction of patients with bladder cancer exhibit responses to 
checkpoint blockade, highlighting a need to better understand drug resistance and identify rational immunotherapy 
combinations. However, accessibility to the tumor prior and during therapy is a major limitation in understanding the 
immune tumor microenvironment (TME). Herein, we identified urine-derived lymphocytes (UDLs) as a readily accessible 
source of T cells in 32 patients with muscle invasive bladder cancer (MIBC). We observed that effector CD8+ and CD4+ 
cells and regulatory T cells within the urine accurately map the immune checkpoint landscape and T cell receptor 
repertoire of the TME. Finally, an increased UDL count, specifically high expression of PD-1 (PD-1hi) on CD8+ at the time of 
cystectomy, was associated with a shorter recurrence-free survival. UDL analysis represents a dynamic liquid biopsy that 
is representative of the bladder immune TME that may be used to identify actionable immuno-oncology (IO) targets with 
potential prognostic value in MIBC.
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Introduction
Immunotherapy trials targeting T cell checkpoint molecules and 
their ligands have demonstrated durable responses in patients 
with advanced bladder cancer. These results using monoclonal 
antibodies targeting programmed death-1 (PD-1; Nivolumab and 
Pembrolizumab) and programmed death-ligand 1 (PD-L1; Atezoli-
zumab, Avelumab, and Durvalumab; Balar et al., 2017; Bellmunt et 
al., 2017; Powles et al., 2017, 2018; Sharma et al., 2017; Patel et al., 
2018) have led to their approval by the US Food and Drug Admin-
istration as second line therapy or as first line therapy in patients 
ineligible for platinum-based chemotherapy.
Despite recent therapeutic advances and clinical successes of 
systemic immunotherapy in bladder cancer, ∼75% of patients do 
not respond to treatment (Bellmunt et al., 2017; Sharma et al., 
2017; Powles et al., 2018). To better understand drug resistance 
and inform the development of novel therapies and rational 
combinations of immunotherapeutic drugs, researchers have 
focused on the characterization of the tumor immune microen-
vironment. To date, much attention has focused toward the eval-
uation of PD-L1 expression, mutational load and intra-tumoral 
T cell infiltration within tumor biopsy specimens taken before 
and/or during therapeutic intervention (Snyder et al., 2014; 
Rizvi et al., 2015; Van Allen et al., 2015; McGranahan et al., 2016; 
Mariathasan et al., 2018). However, in the vast majority of the 
patients, access to longitudinal tumor biopsies before and during 
the course of therapy remains a major limitation given the inva-
sive nature of such procedures (Herbst et al., 2014; Tumeh et al., 
2014; Chen et al., 2016; Choueiri et al., 2016).
In patients with bladder cancer, the urine is a rich source of 
tumor-derived material that could potentially serve as a window 
to bladder tumor immune microenvironment. Several groups 
have investigated the use of urinary based biomarkers for the 
detection of bladder cancer, but their clinical use remains lim-
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ited by the sensitivity and specificity of the assays used (Chou 
et al., 2015). Urinary cell–free DNA has previously been demon-
strated to reflect the bladder tumor genomic microenvironment 
(Birkenkamp-Demtröder et al., 2018), and urinary circulating 
tumor DNA (ctDNA; Togneri et al., 2016) has been associated with 
metastatic relapse in bladder cancer. Furthermore, increased 
numbers of urinary lymphocytes have been documented fol-
lowing intravesical Bacillus Calmette-Guerin immunotherapy in 
patients with non-muscle invasive bladder cancer (NMI BC; de 
Boer et al., 1991a; De Boer et al., 1991b; Pieraerts et al., 2012). How-
ever, in depth characterization of the expression of actionable 
immuno-oncology (IO) targets or their association with clinical 
outcome was not performed in any of these studies and patients 
with muscle invasive bladder cancer (MIBC) were not studied. 
Moreover, the extent to which urinary-derived markers reflect 
the tumor immune microenvironment remains unknown. In 
this study, we evaluated the phenotype of urinary-derived lym-
phocytes (UDLs) to determine their value in the identification of 
actionable IO targets expressed in the tumor microenvironment 
in patients with bladder cancer.
Here, we report for the first time that UDLs exhibit a T cell 
checkpoint phenotype and TCR repertoire reflective of the blad-
der tumor microenvironment and are associated with recur-
rence-free survival in patients with MIBC. Our data supports 
the further evaluation of UDLs as a non-invasive liquid biopsy 
that may be used to inform the activation status, checkpoint land-
scape, and TCR usage of tumor infiltrating lymphocytes (TILs) 
during the course of disease and throughout systemic therapy in 
patients with MIBC.
Results
Viable CD3+ T lymphocytes are detected in the urine of a 
heterogeneous cohort of patients with MIBC
To determine whether lymphocytes could be detected in the 
urine of patients with MIBC, we collected precystectomy urine 
samples in 32 patients undergoing surgery with curative intent 
on the day of cystectomy. The most common histological subtype 
in the patients studied (27/32) was transitional cell carcinoma 
(TCC), and 5/32 patients were diagnosed with squamous cell 
carcinoma (SCC).
In our cohort, 13 patients were treatment naive (all with pri-
mary bladder tumors at surgery), and 19 patients received pre-
vious systemic (neoadjuvant chemotherapy or anti PD-L1) or 
intravesical therapy in the preceding 6 mo. Of the 19 patients 
who received prior therapy, 7 patients developed a complete 
pathological response that had been downstaged to pT0 disease 
(6/7) or carcinoma in situ (1/7). The remaining 12 patients had 
remaining pT2–T4 disease at cystectomy (no complete patholog-
ical response; Fig. 1 and Fig. S1). Tumor specimens were analyzed 
from a total of 25 patients with primary bladder tumors pres-
ent at cystectomy (13 treatment naive and 12 patients following 
previous therapy). Based on previous studies (Daud et al., 2016), 
tissue, urine, or peripheral blood mononuclear cell (PBMC) sam-
ples containing <200 viable CD3+ cells (as determined by flow 
cytometry) were considered nonevaluable for subsequent T cell 
subset and immune checkpoint analyses. In total, 24 urine, 25 
tumor, 31 non-tumor (NT) bladder tissue, and 32 PBMC samples 
were analyzed in the study.
The median volume of urine collected from this cohort was 
50 ml (range, 15–250 ml) with a median viable CD3+ count per 
milliliter of 48.3 (range, 0.1–4,928.9). Irrespective of prior ther-
apy, histology, complete pathological response, and stage, we 
were able to identify 200 or more viable CD3+ UDLs in 20/25 
(80%) of patients with primary bladder tumors present (at least 
pT2) and 4/7 (57.1%) patients who developed a complete patholog-
ical response (Fig. 1 and Fig. S1). CD3+ UDLs were further divided 
into CD8+, CD4+FoxP3− (CD4eff), and CD4+FoxP3+ (T reg) sub-
sets as shown in Fig. 1, with matched TILs, NT lymphocytes, and 
PBMC as shown in Fig. S1. These T cell subsets were gated based 
upon CD3+ within the lymphocyte gate (FSC-A by SSC-A), exclud-
ing doublets and nonviable cells. To exclude the possibility that 
UDL counts were associated with urinary infection, patients re-
cruited to the study with a urine dipstick test positive for nitrites 
were excluded from the cohort. As a control, we also analyzed the 
urine of an age-matched cohort of six healthy volunteers being 
investigated for hematuria (Table S1). Importantly, there was an 
absence of lymphocytes within the urine of these healthy volun-
teers with no known bladder pathology.
UDLs exhibit a similar checkpoint landscape to TILs 
independent of prior therapy
Having identified T lymphocytes in the urine of patients with 
MIBC, we sought to determine whether the immune check-
point landscape of CD8+, CD4eff, and T reg in UDLs would 
faithfully represent that of lymphocytes found within blad-
der tumor microenvironment and NT, gated based upon viable 
CD3+. Due to their immediate clinical relevance, we focused 
our analysis on the expression of key coinhibitory and costim-
ulatory immune checkpoints including PD-1, TIM-3, CTLA-4, 
ICOS, and 4-1BB.
Flow cytometric analysis revealed remarkable similarities in 
the distribution of checkpoints among effector CD8+ and CD4+ 
cells and T reg cells present in UDLs, tumor, and NT tissue that 
were significantly different to PBMC (Fig. S2 A). Significantly 
higher levels of PD-1 were found on effector CD4+ and CD8+ T 
cells within the urine, tumor, and NT compared with PBMCs. 
Moreover, increased ICOS and CTLA-4 expression on CD4eff 
and T reg cells in UDLs, TILs, and NT was detected, as compared 
with PBMC (Fig.  2 A and Fig. S2 A), consistent with previous 
studies (Liakou et al., 2008). Of relevance, the overall pattern of 
immune checkpoint distribution between UDLs, tumor, and NT 
tissue was consistent regardless of prior therapeutic interven-
tion (Fig. 2 B and Fig. S2 A). The costimulatory receptor 4-1BB 
was partially up-regulated on UDL T reg cells compared with 
PBMCs, a trend that was also observed in TILs independent of 
prior therapy. Lastly, TIM-3 was up-regulated in both T reg and 
CD8+ cells predominantly within TILs and UDLs (Fig. 2, A and 
B; and Fig. S2 A). We also observed high levels of TIM-3, ICOS, 
and CTLA-4, in addition to PD-1, on UDLs and TILs from patients 
with SCC (Fig. S2 C). Principal component analysis (PCA) was 
used as an unsupervised technique to further analyze the tumor 
and urine. The PCA values represent a summary of the frequen-
cies of immune checkpoints for the T cell subsets studied in the 
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matched tumor and urine samples for each patient. These PCA 
values showed a positive correlation with a trend toward statis-
tical significance (Spearman’s Rank correlation coefficient, 0.53; 
P = 0.057; Fig. S2 B).
Having found key differences in the checkpoint distribution 
between TILs, UDLs, and NT compared with PBMCs, we com-
pared the expression of multiple checkpoints on CD8+ and CD4+ 
effector T cells to interrogate the phenotypic overlap between 
TILs and UDLs, compared with NT tissue. Using all possible co-
expression checkpoint phenotypes of CD8+ and CD4eff, an un-
supervised hierarchical clustering analysis of CD8+ and CD4eff 
checkpoint expression showed that UDLs and TILs had a more 
similar coexpression checkpoint landscape compared with NT 
(Fig. 2 C and Fig. S3 A). To delineate the checkpoint phenotype 
most likely to account for the clustering of TILs and UDLs, we 
focused on the two checkpoint coexpression phenotypes with 
the largest delta in frequency between TILs and NT (Table S2). 
Within CD8+ T cells, we found that the hierarchical clustering 
of UDLs and TILs was predominantly driven by PD-1/TIM-3, fol-
lowed by PD-1/ICOS coexpression on CD8+ T cells. In contrast, 
the similarity observed between effector CD4+ T cells within TILs 
and UDLs was largely accounted for by ICOS/CTLA-4, followed by 
CTLA-4/TIM-3 coexpression (Table S2).
In line with the above, the frequency of CD8+ cells coexpress-
ing PD-1/TIM-3 was significantly higher in UDLs and TILs as 
compared with NT tissue (Fig. 2 D). Importantly, no significant 
difference was observed in the frequency of CD8+ coexpress-
ing PD-1/TIM-3 between UDLs and TILs (Fig.  2  D), suggestive 
of chronic antigenic stimulation of CD8+ cells found within the 
tumor and urine, compared with NT. Among the effector CD4+ T 
cell compartment, the frequency of cells coexpressing ICOS and 
CTLA-4 was similar in UDLs and TILs (Fig. S3 B).
The data obtained from three patients selected as repre-
sentative of the different histological subtypes and treatment 
histories in our cohort (BL 33, TCC treatment naive; BL 55, 
SCC treatment naive; BL 42, TCC neoadjuvant anti–PD-L1) was 
analyzed using the visualization software: Simplified Presen-
tation of Incredibly Complex Evaluations (SPI CE; Roederer et 
al., 2011). This different mode of analysis also showed a high 
degree of concordance in the coexpression phenotype of CD8+ 
(Fig. 2 E) and CD4eff (Fig. S3 C) among UDLs and tumor with 
remarkably high levels of PD-1/TIM-3 coexpression on CD8+ 
Figure 1. Viable CD3+ T lymphocytes are detected in the urine of a heterogeneous cohort of patients with MIBC. The proportion of CD8+, CD4+ FoxP3− 
(CD4eff), and CD4+ FoxP3+ (T reg) cells present within the viable CD3+ gate in the urine is shown. Samples containing <200 viable CD3+ on flow cytometry 
were deemed unevaluable for further T cell subset analysis and are highlighted in gray (not evaluable). Each patient’s prior treatment history, histological 
diagnosis, complete pathological response to therapy, clinical outcome (recurrence or death), pathological tumor stage, and urine count per milliliter is shown. 
No complete pathological response was defined as presence of pT2–T4 disease. A complete pathological response was defined as pT0 disease. BCG, Bacillus 
Calmette-Guerin; NA, not applicable; NAC, neoadjuvant chemotherapy; PD-L1, programmed death-ligand 1.
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Figure 2. UDLs exhibit a similar checkpoint landscape to tumor-infiltrating lymphocytes independent of prior therapy. Single level expression and 
coexpression of B7 and TNFR superfamily coinhibitory and costimulatory molecules on T cell subsets were quantified by flow cytometry in matched urine, tumor, 
NT tissue, and PBMCs obtained from all patients. (A and B) Heat map depicts the mean percentage of CD8+, CD4eff, and T reg cells expressing individual immune 
checkpoint molecules in urine, tumor, NT, and PBMC samples obtained from treatment naive patients (n = 13; A), and patients that received prior systemic 
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(Fig.  2, D and F) and ICOS/CTLA-4 coexpression on CD4eff 
(Fig. S3, B and D).
Collectively, the findings above are consistent with our hy-
pothesis that the UDL population is largely derived from cells 
shed from the tumor into the urine and represent a window to 
the checkpoint landscape of lymphocytes within the tumor in 
patients with MIBC.
The TCR repertoire of UDLs reflects the intra-
tumoral repertoire
Since each TCR sequence is produced with very low probabil-
ity (Murugan et al., 2012), two T cells expressing the same TCR 
sequence are likely to be part of the same clone. The TCR rep-
ertoire therefore provides a powerful way to probe how two T 
cell populations are related. We therefore sequenced the TCR 
repertoires of UDLs, tumor, NT tissue, and PBMCs in a subgroup 
of patients with matched RNA available. The total numbers of α 
and β complementary determining region 3 (CDR3s) that were 
sequenced in each of the compartments are shown in the Table 
S3. A strong correlation was observed between the number of 
α and β TCRs sequenced, reflecting the reproducibility of the 
sequencing method (Spearman’s Rank correlation coefficient, 
0.96; P < 0.0001).
The TCR abundance distribution (i.e., the proportion of the 
repertoire which is made up of TCRs which occur only once, 
twice, three times, etc.) of the four populations combined from 
all the patients is shown for β TCRs (Fig. 3 A) and for α TCRs (Fig. 
S4 A). The clonal structure of the TCR repertoire was similar 
across tumor, urine, NT tissue, and PBMC samples, therefore 
any differences observed in the TCR landscape of these compart-
ments was unlikely due to differences in the distribution of the 
repertoire of T cells.
Having noted a similar TCR distribution across all of the com-
partments studied, we next examined the relationship between 
the repertoires at the level of the individual CDR3 sequences. 
For each individual patient, unsupervised hierarchical cluster-
ing of CDR3 frequencies reproducibly clustered the urine TCR 
sequences with the tumor TCR sequences for β (Fig. 3 B) and 
α (Fig. S4 B). To confirm the statistical significance of this re-
lationship, we modeled the urine as a subsample of one of the 
other populations. We repeatedly sampled from each repertoire 
and measured the Jaccard index and repertoire similarity of 
each sample with an equal sized sample from the urine reper-
toire (see Materials and methods for details). This bootstrap ap-
proach allowed us to compare the repertoire similarity between 
the urine and other samples quantitatively. As shown in Fig. 3 
(C and D), for β TCRs, the similarity of urine to the tumor was 
much greater than to either NT tissue or blood (P < 0.0001), 
whether using the Jaccard index, which measures the number 
of shared sequences without regard to abundance, or the sim-
ilarity metric, which takes into account the abundance of the 
shared CDR3s. This pattern was also observed within the α TCR 
repertoire (Fig. S4, C and D).
Expanded T cell clones within the tumor may represent an 
important source for the cellular immunotherapy of cancer. 
We therefore examined whether TCRs found at high abundance 
within the tumor could also be found within urine, since urine 
would potentially provide an easier source of such cells for adop-
tive therapy protocols. Several of the 10 most abundant TCRs in 
tumor were indeed found within urine. In contrast, few of the ex-
panded α and β CDR3 sequences in the urine were found among 
the 10 most expanded CDR3 sequences in NT tissue and PBMC 
samples (Fig. 3 E and Fig. S4 E).
Together, these data demonstrate that the urine contains a 
population of lymphocytes that closely reflect the tumor infil-
trating TCR repertoire and are suggestive of similar antigenic 
specificities of UDLs and TILs.
Increased urinary CD3+CD8+PD-1hi lymphocytes are associated 
with a worse clinical outcome in patients with MIBC
Given that the T cell checkpoint phenotype and TCR repertoire 
underscored the role of UDLs as a surrogate for the TIL pheno-
type and TCR repertoire and that TILs have previously been asso-
ciated with survival in various solid tumors (Gooden et al., 2011), 
we sought to determine whether the presence of T cells in the 
urine was associated with tumor stage, response, and/or recur-
rence-free survival in patients with MIBC. The 32 patients were 
followed up for a median time of 8 mo.
First, we assessed whether the UDL count, taken on the day 
of cystectomy (number of events recorded within viable CD3+ 
gate on the flow cytometer) correlated with pathological tumor 
stage and treatment response as a low pathological stage and 
response to neoadjuvant therapy are associated with improved 
recurrence-free survival (Grossman et al., 2003). We used a stan-
dardized measure of UDL count (per milliliter of urine) given the 
variation of urine volumes collected within the patient cohort. 
Although a similar UDL concentration was found for patients 
with T0, T2, or T3 disease, a significantly higher UDL concen-
tration was found in patients with T4 tumors compared with T0 
tumors (median 150.6 vs. 5.45 UDL count/ml; P = 0.009), sug-
gesting that locally advanced tumors may be more likely to gen-
erate UDLs (Fig. 4 A). We also observed that those patients that 
therapy (n = 19; B). (C) Displayed is an unsupervised clustering heat map of the mean frequencies of CD8+ cells demonstrating each of the coexpression immune 
checkpoint phenotypes in found tumor, urine, and NT tissue. Each row within the heat map represents a different immune checkpoint coexpression phenotype. 
Key represents the markers that define each of the coexpression phenotypes: presence of marker (black circles) or absence of marker (white circles). Only CD8+ 
coexpression phenotypes found at a frequency of ≥1% (mean across all patients) in any of tumor, urine, or NT are shown. (D) Graph depicts the frequency of 
CD8+ T cells that coexpress PD-1 and TIM-3 in tumor, urine, and NT samples. P values were calculated using paired t test. Bars represent mean values with SD. 
*, P < 0.05; **, P < 0.005; NS, not significant. (E) SPI CE analysis of all CD8+ T cells displaying the coexpression of checkpoint molecules in urine, tumor, NT, 
and PBMC in a representative group of patients (BL 33, TCC treatment naive; BL 55, SCC treatment naive; BL 42, TCC neoadjuvant immunotherapy). Pie charts 
depict qualitative distribution of checkpoint expressions on CD8+ T cells. Arcs show checkpoint makeup and overlap within pie slice. (F) Coexpression pattern 
of PD-1/TIM-3 on CD8+ on urine, tumor, and NT. Dot plots display the phenotype of CD8+ lymphocytes from matched samples from the same representative 
patients in E (BL 33, BL 55, and BL 42). The percentage of cells expressing each combination of checkpoint molecules is shown.
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Figure 3. The TCR repertoire of UDLs reflects the intra-tumoral repertoire. (A) The distribution of β chain TCRs in the urine is similar to tumor, NT tissue, 
and PBMCs. The proportion of TCRs found with different abundances (x axis) in urine, tumor, NT tissue, and PBMCs is shown. (B) Hierarchical clustering of CDR3s 
demonstrates similarity in the TCR repertoire of urine and tumor. CDR3s were filtered based on abundance (present at least eight times) and detected in at least 
one of urine, tumor, or NT tissue. Color key represents the proportion of each CDR3 within the whole repertoire. T, tumor; U, urine; B, PBMC. (C) The overlap, 
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achieved a complete pathological response to systemic therapy 
had a significantly lower UDL count on the day of cystectomy as 
compared with patients that were treatment naive (median 5.45 
vs. 194.1 UDL count per/ml; P = 0.03; Fig. 4 B). However, there was 
no statistically significant difference in the UDL count among 
patients that had primary tumors present at surgery (treatment 
naive versus nonresponding patients). In addition, no signif-
icant difference in UDL count was observed between patients 
that achieved a complete pathological response and those that 
did not. We next evaluated whether UDL count could be associ-
ated with disease recurrence. We found that disease recurrence 
was significantly associated with a higher UDL concentration 
detected at the time of cystectomy (1,003 vs. 17.82 UDL count/
ml, P = <0.0001; Fig. 4 C).
When dividing patients into two groups based on the me-
dian UDL count, we observed that patients with a low UDL count 
(below the median) did not develop recurrence of their disease 
(Fig. 4 D), in contrast to patients with a high UDL concentration 
that had a poorer recurrence-free survival (UDL count above the 
median; P = 0.0004). Next, when considering UDL count as a 
continuous variable and performing a natural log transformation 
(Fig. S5 A), the unadjusted hazard ratio (HR) was calculated as 
1.80 (95% confidence interval [CI], 1.22–2.63; P = 0.003).
Given the potential confounding effect of tumor stage and 
treatment response on the UDL count, we performed statistical 
adjustment for these variables using a Cox regression model (Fig. 
S5 A). Notably the association between higher UDL count/ml and 
a poorer recurrence-free survival remained statistically signifi-
cant when adjusted for pathological tumor stage (adjusted HR, 
1.49; 95% CI, 1.02–2.17; P = 0.04), or treatment response with an 
adjusted HR of 1.61 (95% CI, 1.06 – 2.46; P = 0.026). The multivar-
iate analysis when stratified for both tumor stage and response 
was not statistically significant, with an adjusted HR of 1.43 (95% 
CI, 0.92–2.21, P = 0.108).
Having observed that patients with an increased urinary CD3+ 
count were more likely to experience disease relapse, we next 
assessed whether there were any checkpoint phenotypes that 
may account for this result. We did not observe any significant 
differences in survival when considering urinary CD3+PD-1+ or 
CD8+PD-1+TIM-3+ cells. Previous work has shown that CD8+ TILs 
with the highest expression of PD-1 is associated with tumor re-
activity, reflective of chronic antigenic stimulation resulting in a 
dysfunctional and exhaustive state (Blackburn et al., 2008; Paley 
et al., 2012; Thommen et al., 2015, 2018; Reading et al., 2018). In 
line with previous work, (Thommen et al., 2018) we classified 
CD8+PD-1+ T cells into high and low categories; cells considered 
to be PD-1hi were those with expression levels of PD-1 expression 
greater than that observed in matched PBMC samples (Fig. S5 B). 
We next considered whether an increased frequency of levels of 
PD-1hi CD8+ UDLs was related to survival.
Interestingly, we observed that the frequency of CD8+PD-1hi 
cells was significantly higher in UDLs (P = 0.01) and TILs (P = 
0.0004) as compared with NT tissue (Fig. 4 E). Importantly, no sig-
nificant difference was observed in the frequency of CD8+PD-1hi 
cells between UDLs and TILs (Fig. 4 E), suggestive of chronic an-
tigenic stimulation of these cells. The natural log UDL CD3 count/
ml significantly correlated with CD8+PD-1hi expression in both 
UDLs (Spearman’s Rank correlation coefficient, 0.62; P = 0.0012; 
Fig. 4 F) and TILs (Spearman’s Rank correlation coefficient, 0.68; 
P = 0.0002; Fig. S5 C). Finally, we demonstrated that patients 
with increased levels of CD8+PD-1hi cells (above the median) were 
more likely to develop recurrence of their disease compared with 
those with low levels of CD8+PD-1hi (below the median), with a 
highly significant P value of 0.0009, with an unadjusted HR of 
4.3 (95% CI, 1.02–18.23; P = 0.048).
Collectively, these data highlight the potential prognostic role 
of the UDL count and CD8+ phenotype in patients with MIBC that 
requires validation in a prospective study.
Discussion
Our results demonstrate for the first time that urine-derived 
lymphocytes in patients with MIBC exhibit a T cell checkpoint 
phenotype and TCR repertoire that overlaps with lymphocytes 
infiltrating the bladder tumor microenvironment. Remarkably, 
this similarity was observed in a heterogeneous cohort of 32 
patients undergoing cystectomy that included patients with dif-
ferent stages of disease, treatment histories, and histological sub-
types. Furthermore, we demonstrated that patients with a high 
urinary lymphocyte count were more likely to relapse of bladder 
cancer, reflecting the potential prognostic value of UDL analysis.
Given the similarity in the coexpression T cell checkpoint 
landscape and TCR repertoire between UDLs and TILs and the 
absence of UDLs in the urine of healthy individuals (Table S1), 
it is plausible that UDLs are derived from the tumor tissue itself, 
although the mechanisms by which lymphocytes enter the urine 
remain elusive. Factors that may regulate release of TILs into 
the urine include the extent of tumor invasion, necrosis, or mi-
crovessel density, resulting in leakage and exfoliation of tumor 
cells and infiltrating lymphocytes into the urine, all of which 
would be worthy of future study.
Current clinical studies in bladder cancer typically include the 
collection of peripheral blood samples in an attempt to gain in-
sight into the evolving bladder tumor microenvironment. Strik-
ingly, our data demonstrate minimal phenotypic and repertoire 
overlap between PBMC and TILs and instead suggest that UDLs 
better recapitulate the bladder T cell and immune checkpoint 
landscape that may be relevant for future clinical studies.
The overlap between TILs and UDLs was well exemplified by 
similarly high levels of PD-1 and TIM-3 CD8+ coexpression in 
quantified by the Jaccard index, between the set of CDR3s found in urine and in each of the other compartments is shown. The results show the mean plus SD. 
The significance was measured by one-way ANO VA. (D) Similarity index (measured as the dot product of the abundances) between samples of the urine TCR 
repertoire and the repertoire of each other compartment. The results show the mean plus SD. The significance was measured by one-way ANO VA. (E) The most 
expanded CDR3s detected in the tumor are also expanded within the urine. Pie charts represent the 10 most abundant βCDR3s ranked in descending order in 
the urine, tumor, NT, and PBMCs. CDR3s among the top 10 CDR3s present in at least two of tumor, urine, tumor, NT tissue, and PBMCs are highlighted in color. 
Gray represents CDR3s that are not shared. ****, P < 0.0001 for C and D.
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both compartments: a phenotype associated with chronic anti-
genic stimulation and impaired T cell function (Sakuishi et al., 
2010; Gros et al., 2014). We also observed similar levels of ICOS 
and CTLA-4 coexpression on CD4eff within TILs and UDLs. A 
similar expression pattern has been previously documented in 
bladder cancer CD4+ TILs following anti–CTLA-4 therapy (Liakou 
et al., 2008). The phenotypic and repertoire concordances be-
tween TILs and UDLs across treated and untreated patients sup-
port the use of UDLs in the longitudinal evaluation of the bladder 
tumor immune microenvironment, for example in the context of 
immunotherapeutic clinical trials.
Given the array of checkpoint molecules expressed on the 
surface of lymphocytes within the urine, UDL analysis may also 
be used to explore the checkpoint landscape throughout therapy, 
with the potential to inform subsequent actionable IO targets in 
patients with MIBC. Given the high percentage of TIM-3, CTLA-4, 
and ICOS coexpressed with PD-1 on effector T cell subsets within 
the tumor microenvironment, further investigation exploring 
the therapeutic targeting of these molecules, either alone or in 
conjunction with PD-1/PD-L1 blockade, is warranted. A high 
level of TIM-3, ICOS, and CTLA-4, in addition to PD-1, was ob-
served on UDLs and TILs from patients with SCC. Of relevance, 
this is a histological subtype largely excluded from clinical trials 
of checkpoint blockade, with limited treatment options in the 
clinical setting. Our findings suggest that patients with SCC may 
benefit from immunotherapy directed against these targets and 
may warrant inclusion in future clinical trials.
In addition to checkpoint molecules, the use of TCR repertoire 
analysis of UDLs may be used as a tool to track T cell dynamics 
throughout immunotherapy, providing insight into the specific-
ity of immune response. Whether RNA from UDLs could also be 
used to characterize and unveil changes in the transcriptional 
program of tumor-reactive T cells through therapy remains to 
be determined. Moreover, given the potential tumor reactivity of 
UDLs, they may provide a convenient and easily accessible source 
of cells for in vitro expansion and subsequent adoptive cellular 
immunotherapy for patients with MIBC, although this needs to 
be explored further.
The demonstration that the UDL phenotype and repertoire 
overlaps with tumor lymphocyte populations, and that the 
number of UDLs is related to disease outcome suggests that 
UDL analysis may complement the use of urinary ctDNA in pa-
Figure 4. Increased urinary CD3+CD8+PD-1hi lymphocytes are associated with a worse clinical outcome in patients with MIBC. Displayed is the associ-
ation of urinary lymphocyte count with clinical outcome. (A and B) UDL count/ml and relationship with pathological tumor stage (A) and response to treatment 
(B) is shown. (C) The association of disease recurrence and UDL count is shown. Mann-Whitney U test used for statistical analysis. Error bars represent mean 
values with SD. (D) Recurrence-free survival (%) over a median follow up of 8 mo is shown according to whether patients were found to have a high UDL count 
(above the median) or a low UDL count (below the median). (E) Graph depicts the frequency of CD8+PD-1hi T cells in tumor, urine, and NT tissue samples. 
Mann-Whitney U test used for statistical analysis. Error bars represent mean values with SD. (F) Displayed is a Spearman rank correlation of the frequency of 
CD3+CD8+PD-1hi in UDL (%) and the natural log CD3 count/ml in urine samples. Spearman rank correlation coefficient and P values shown. (G) Recurrence-free 
survival (%) over a median follow up of 8 mo is shown according to whether patients had a high frequency of PD-1hi (above the median) or a low frequency of 
PD-1hi (below the median). *, P < 0.05; **, P < 0.005; ***, P < 0.0005; ****, P < 0.0001; NS, not significant for A–C and E.
Wong et al. 
UDLs as a non-invasive measure of the bladder TME in MIBC
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20181003
2756
tients with bladder cancer in combination, providing insight 
into both the immune and genetic landscape within the tumor 
microenvironment.
Our findings also demonstrated that patients were 1.8 times 
more likely to relapse of bladder cancer for every log unit in-
crease in UDL count. Moreover, we found that an increased UDL 
count was associated with pathological tumor stage and response 
to systemic therapy, highlighting the intricate relationship be-
tween UDL count, tumor stage, and treatment response. While 
increased intra-tumoral T cell infiltration has previously been 
associated with improved clinical outcome in a variety of tumor 
types including MIBC (Sharma et al., 2007), our data suggest that 
the presence of UDLs are associated with a worse clinical out-
come. Importantly, UDL count and TIL count are two separate 
entities, and an increased TIL count may be reflective of an ongo-
ing anti-tumoral immune response, as previously described, thus 
associated with a favorable clinical outcome (Gooden et al., 2011).
The biological significance of an increased UDL count was 
subsequently explored to gain a better understanding of the 
possible underlying mechanism(s) that may explain the ob-
served relationship between increased UDL count and poorer 
clinical outcomes. Given that PD-1 expression has previously 
shown to identify tumor reactive T cells (Inozume et al., 2010; 
Gros et al., 2014; McGranahan et al., 2016), and T cells with the 
highest level of PD-1 expression are associated with distinct tran-
scriptomic, phenotypic, and functional properties (Thommen et 
al., 2015, 2018; Reading et al., 2018; Zappasodi et al., 2018), we 
next assessed the PD-1 expression levels of UDLs and correlated 
this with clinical outcome. We observed a similar frequency of 
CD8+PD-1hi cells in urine and tumor samples, which was signifi-
cantly higher than NT tissue. Additionally, a significant positive 
correlation was observed between UDL count/ml and the fre-
quency of CD8+PD-1hi UDLs and TILs. The mechanism underlying 
this observation currently remains unclear, but may be reflective 
of (1) tumor inflammation, (2) expansion and/or differentiation 
of CD8+PD1hi cells, in response to chronic tumor antigen expo-
sure, and (3) loss of basement membrane integrity during anti-
gen specific T cells responses in the bladder.
Importantly, we found that patients with increased frequency 
of CD8+PD1hi UDLs were more likely to experience disease re-
lapse, highlighting the potential clinical relevance of CD8+PD1hi 
UDLs that requires further prospective validation. Moreover, in-
creased PD-1 expression consistent with chronic antigenic expo-
sure and T cell dysfunction has previously been correlated with 
worse disease-free survival in head and neck cancer (Kansy et 
al., 2017). While it is plausible that CD8+PD-1hi UDLs may point 
toward tumor reactivity, it is not possible to fully conclude this. 
Accordingly, further phenotypic and functional studies, includ-
ing bulk RNA or single cell RNA sequencing aimed at evaluating 
the antigenic specificity and biological mechanisms leading to 
UDL generation warrant further investigation.
We recognize that our findings are based on a relatively small 
sample size of a heterogeneous cohort of patients in terms of his-
tological subtype, treatment histories, and treatment response. 
However, despite the marked heterogeneity, the flow phenotype 
and TCR repertoire remain similar between urine and tumor, sug-
gesting that urinary lymphocytes are dynamic and may be able 
to recapitulate the tumor microenvironment at that time point. 
Further prospective studies in a larger cohort of patients, consid-
ering the above, are required to corroborate our preliminary find-
ings and validate the hypothesis that UDL count and phenotype is 
prognostic in MIBC. Importantly, UDL analysis is most relevant in 
patients who have not undergone cystectomy. It is estimated that 
∼60% of patients with metastatic bladder cancer present with de 
novo metastatic disease with the primary bladder cancer in situ 
(Pal et al., 2015). In addition, approximately a quarter of patients 
with metastatic bladder cancer will have received bladder sparing 
primary therapy such as radiotherapy, with a proportion likely to 
have tumor relapse within the bladder. Thus, UDL analysis is not 
only likely to have utility in the assessment of patients with mus-
cle invasive localized disease, but could be important for the lon-
gitudinal evaluation of patients with metastatic bladder cancer 
with their primary bladder cancer in situ undergoing systemics 
therapy. Indeed, for this latter group, our preliminary data show 
the presence of UDLs and indicated dynamic immune checkpoint 
phenotype changes throughout therapy (unpublished data). This 
is work that is ongoing and an area of future study. Lastly, our 
current study is very much T cell focused, and we plan to explore 
the urinary myeloid compartment in subsequent studies.
In conclusion, we have identified UDLs as a readily accessible 
source of T cells from patients with MIBC that accurately map 
the immune landscape and repertoire of lymphocytes within 
the tumor microenvironment within a heterogeneous cohort of 
patients. These findings warrant a trial in a larger independent 
cohort of patients to firmly validate the use of UDL analysis as 
a novel, clinically useful liquid biopsy with potential prognos-
tic implications.
Materials and methods
Study design
Matched bladder tumor, NT tissue urothelium, urine, and PBMCs 
were collected from 32 patients undergoing radical cystectomy. 
The patient cohort comprised of those initially diagnosed with 
MIBC. The cohort included patients that were either treatment 
naive (n = 13) or those that had received prior therapy (chemo-
therapy, immunotherapy, or Bacillus Calmette-Guerin) during 
the 6 mo preceding cystectomy (n = 19).
Isolation of lymphocytes from peripheral blood and urine
On the day of radical cystectomy, fresh urine and blood samples 
were obtained before the start of surgery. Peripheral blood was 
collected into 10-ml EDTA tubes. Urine was collected in the morn-
ing of cystectomy into a universal container. All urine samples 
were tested by dipstick for the presence of infection. Any sample 
that tested positive for nitrites was excluded from further analy-
ses. PBMC and UDLs were isolated through density-gradient cen-
trifugation using Ficoll-Paque PLUS (GE Healthcare). Live cells 
were stained fresh following isolation. Excess sample not used 
for staining was frozen at −80°C and stored in liquid nitrogen.
Isolation of lymphocytes from tumor and NT tissue samples
Following radical cystectomy, the bladder specimen was dis-
sected, and NT tissue was sampled from the contralateral side 
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to the tumor as identified macroscopically. All tissue samples 
were placed into conical tubes containing plain RPMI culture 
medium (Sigma) and transferred locally on the day of collection 
for processing. Tumor samples were micro dissected manually 
and digested with Collagenase (2.5 mg/ml; Gibco) and DNase I 
(0.2 mg/ml; Roche) at 37°C for 1 h, homogenized using gentle-
MACS (Miltenyi Biotech), and filtered through a 0.7-µm cell 
mesh. Leukocytes were enriched by gradient centrifugation with 
Ficoll-paque (GE Healthcare). Once isolated, single cell suspen-
sions of lymphocytes were stained fresh on the day of process-
ing. Excess sample not used for staining was frozen at −80°C and 
stored in liquid nitrogen. All tissue samples from cystectomy 
were verified using immunohistochemistry by a consultant his-
topathologist specializing in uro-oncology.
Flow cytometry
Acquisition was performed with a BD LSR II Fortessa (BD Bio-
sciences). The following antibodies and fluorescent labels were 
used in the flow cytometry experiments: from Biolegend, PD-
1-Q605 (EH12.2H7), CD25-BV711 (BC96), CD3-BV785 (OKT3), CT-
LA-4-APC (L3D10), ICOS-APC (C398.4A), and 4-1BB-PE (4B4-1); 
from BD Biosciences, Granzyme B-V450 (GB11), CD8-V510 (SK1), 
and TIM-3-Q650 (7D3); from eBioscience, FoxP3-PE (PCH101), 
CD4-AF700 (OKT4), and fixable viability dye-e780. Intranuclear 
staining of FoxP3 and Ki67 was performed using the FoxP3 Tran-
scription Factor Staining Buffer Set (eBioscience).
TCR sequencing
The α and β chains of the TCR repertoire were sequenced using 
a method which starts with total RNA isolated from unfraction-
ated tissue/cells and introduces unique molecular identifiers at-
tached to individual cDNA molecules to provide a quantitative 
and reproducible method of library preparation. RNA was ex-
tracted from tissue or PBMC samples using standard silica mem-
brane columns (AllPrep DNA/RNA Mini kit or RNeasy Micro or 
Mini kits; Qiagen). Full details for both the experimental library 
preparation and the subsequent computational analysis using 
Decombinator is published in Oakes et al. (2017). For each sample, 
the output provides a list of CDR3 sequences and the number of 
times each CDR3 is observed.
The Jaccard index between two repertoires is calculated as 
the intersection between two sets of TCRs (i.e., the number of 
shared CDR3 sequences) divided by the union (the sum of the 
number of unique sequences in both sets). The similarity be-
tween two samples was measured using a standard similarity 
metric, calculated as the dot product between the vector of CDR3 
frequencies in each sample. In Fig. 3 (C and D), we subsampled 
the combined repertoires from each compartment. Each sample 
contained 1,000 unique CDR3s. Each sample from tumor, NT tis-
sue and blood was compared with an equal sized sample from 
the urine. The sampling was repeated 100 times, and the figure 
shows the average and SD. Statistical analysis was performed 
using a one-way ANO VA.
Flow cytometry statistical analysis
Flow cytometry data analysis was performed in FlowJo version 
10.0.8 (Tree Star Inc.). Statistical analyses were performed in 
Prism 6 (GraphPad Software, Inc.); P values were calculated 
using Kruskall-Wallis analysis of variance and Dunn’s post-hoc 
test with error bars represent mean values with SEM, unless oth-
erwise indicated in the figure legends (NS, P > 0.05; *, P ≤ 0.05; 
**, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001). <200 viable CD3+ cells 
were defined as inadequate number of cells for analysis. Analy-
sis of Kaplan-Meier survival curves was performed with use of 
the log-rank test.
Human study oversight
Collection of human tissue for this study was agreed by the in-
stitutional review board as part of the University College Lon-
don/University College London Hospital BioBank for Health 
and Human Disease (REC 15/YH/0311) study. All patients (or 
their legal representatives) provided written informed consent 
before enrolment.
Online supplemental material
Fig. S1 shows the proportion of T cell subsets within CD3+ T 
lymphocytes in matched tumor, NT tissue, and PBMCs. Fig. S2 
supports the findings in Fig. 2, showing the statistical evaluation 
of the of immune checkpoint molecule expression on the T cell 
subsets, including SCC. In Fig. S3, effector CD4+ T cells also ex-
hibit a similar coexpression checkpoint phenotype in UDLs and 
TILs. Fig. S4 demonstrates the corresponding α TCR repertoire of 
UDLs, which reflects the intra-tumoral repertoire. Fig. S5 com-
plements Fig. 4, showing that increased urinary CD3+CD8+PD-1hi 
lymphocytes are associated with a worse clinical outcome in 
patients with MIBC. The UDL counts in age-matched patients 
with no known bladder pathology are shown in Table S1. Table 
S2 demonstrates the delta frequency difference between tumor 
and NT tissue checkpoint coexpression phenotypes within the 
effector T cells in descending order. The largest delta frequencies 
were used for Fig. 2 (D and F) and Fig S3 (B and D). Finally, Table 
S3 shows the total numbers of α and β CDR3s sequenced.
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